Prescient Therapeutics Investor Replay – CellPryme-A
Prescient Therapeutics CellPryme-A Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics CellPryme-A Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.